Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03194139
Recruitment Status : Completed
First Posted : June 21, 2017
Last Update Posted : February 14, 2018
Sponsor:
Collaborator:
Syneos Health
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Brief Summary:

The study will be a double-blind, randomized, crossover, single-dose assessment of IV-administered GC4711 compared to GC4419 in healthy volunteers.

Consenting subjects will undergo screening procedures within 28 days of the start of dosing. Pharmacokinetics (parent drug and major metabolites) will be assessed in plasma and urine from all subjects.

Initially, a sentinel cohort of 4 subjects, will be enrolled; each eligible subject will receive single dose of GC4711 IV at dose of 30 mg over one hour. Following a clinical safety review by the Galera study team , if no safety concerns are identified after the last subject completes study participation, enrollment will continue in 2 stages to a crossover study design. In stage 1, 12 subjects will be enrolled and in stage 2, if no safety concerns are identified in stage 1 following a clinical safety review by the Galera study team, 20 subjects will be enrolled. In both enrollment stages, eligible subjects in the crossover design will be randomized in 1:1 ratio to one of two treatment sequences: Test (GC4711) -> Ref (GC4419) or Ref (GC4419) -> Test (GC4711). On Day 1, subjects will receive the first treatment they were randomized to, and on Day 4 (following a washout), they will receive the second treatment. Subjects will be followed up for 2 days after the second treatment.


Condition or disease Intervention/treatment Phase
Healthy Volunteers Healthy Drug: GC4711 30 mg IV Drug: GC4711 50 mg IV Drug: GC4419 45 mg IV Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Crossover, Single Dose Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers
Actual Study Start Date : September 25, 2017
Actual Primary Completion Date : December 24, 2017
Actual Study Completion Date : December 24, 2017

Arm Intervention/treatment
Experimental: Sentinel Cohort Drug: GC4711 30 mg IV
GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump

Experimental: Crossover Design Drug: GC4711 50 mg IV
GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.

Drug: GC4419 45 mg IV
GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.




Primary Outcome Measures :
  1. Frequency, duration, and severity of adverse events (AEs) [ Time Frame: From first dose of study medication until up to 3 days post last dose. Up to 6 days total ]
  2. Incidence of clinically significant laboratory abnormalities [ Time Frame: From first dose of study medication until up to 3 days post last dose. Up to 6 days total ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy men and women between 18 and 50 years (inclusive) of age;
  2. Subjects who provide written informed consent to participate in the study
  3. Body Mass Index (BMI) 18 to 32 kg/m2 (inclusive) and weighing at least 50 kg during Screening and at Baseline.
  4. Subjects in general good health
  5. Chest X-ray free of clinically significant abnormalities
  6. Blood pressure and heart rate within normal limits
  7. Female subjects must:

    1. Have a negative pregnancy test during Screening and Baseline
    2. Be non-lactating
    3. Be at least two years postmenopausal, surgically sterile or practicing effective contraception

Exclusion Criteria:

  1. History of clinically significant illness, disease, medical condition, or laboratory abnormality
  2. Known hypersensitivity and/or allergy to study drugs
  3. Use of any prescription or over-the-counter medication within one week prior to baseline;
  4. Anticipated need for any medication during the course of the study
  5. Use of nitrates or erectile dysfunction drugs such as phosphodiesterase type 5 (PDE 5) inhibitors (e.g., sildenafil, tadalafil, or similar agents), from 24 hours prior to screening throughout participation in the study;
  6. Use of or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure, from 24 hours prior to screening throughout participation in the study;
  7. Use of any vitamin or mineral supplement 24 hours prior to dosing, or anticipated use of any vitamin or mineral supplement throughout the duration of the study;
  8. Positive HIV, Hepatitis B or Hepatitis C
  9. Known history of substance abuse, drug addiction, or alcoholism within 3 years prior to Baseline;
  10. Anticipated inability to abstain from alcohol, tobacco, or caffeine use from 48 hours prior to the administration of study drug and throughout the duration of the study;
  11. History of smoking or any use of a tobacco product within six months prior to Baseline;
  12. Donation of blood or blood products within 30 days prior to the Baseline;
  13. Receipt of an investigational test substance within three months prior to the first dose of study drugs or anticipated receiving any study drugs (including placebo on another investigational study)
  14. Subject has previously participated in this study, or in a prior study of GC4419 or GC4702.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03194139


Locations
Layout table for location information
Australia, Victoria
Nucleus Network Limited
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
Galera Therapeutics, Inc.
Syneos Health
Investigators
Layout table for investigator information
Study Chair: Jon T Holmlund, MD Galera Therapeutics

Layout table for additonal information
Responsible Party: Galera Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03194139     History of Changes
Other Study ID Numbers: GTI-4711-001
First Posted: June 21, 2017    Key Record Dates
Last Update Posted: February 14, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Galera Therapeutics, Inc.:
Healthy Adult
Superoxide Dismutase
First in Human
Free Radical Dismutase
Additional relevant MeSH terms:
Layout table for MeSH terms
Superoxide Dismutase
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs